{"entity":{"id":"tpst-4003","kind":"drug","name":"TPST-4003","aka":[],"tldr":"TPST-4003 is a treatment from Tempest Therapeutics meant to turn a patient's T cells into cancer-hunting CAR-T cells inside the body, aimed at two markers on B cells and plasma cells.","summary":"TPST-4003 is Tempest Therapeutics' lead programme, a dual CD19 and BCMA in vivo CAR-T candidate that Tempest is developing for indications in immunology and oncology. The August 2026 registration statement does not state its stage.","asOf":"2026-11-04","links":[{"label":"SEC: Tempest Therapeutics Form S-1, August 2026","url":"https://www.sec.gov/Archives/edgar/data/1544227/000119312526361240/d181522ds1.htm"}],"tags":["pipeline"],"related":[],"cancers":[],"sections":[],"technologies":["in-vivo-car-t"],"targets":["cd19","bcma"],"drugs":[],"companies":["tempest-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo startup monitors","editedOn":"2026-11-04"},"code":"TPST-4003","modality":"In vivo CAR-T (dual CD19 and BCMA)","mechanism":"A dual-targeting CD19 and BCMA chimeric antigen receptor generated in the patient's own T cells inside the body, as described by Tempest Therapeutics.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/tpst-4003/","neighbours":{"technology":[{"id":"in-vivo-car-t","kind":"technology","name":"In vivo CAR-T","route":"/technologies/in-vivo-car-t/"}],"target":[{"id":"bcma","kind":"target","name":"BCMA","route":"/targets/bcma/"},{"id":"cd19","kind":"target","name":"CD19","route":"/targets/cd19/"}],"company":[{"id":"tempest-therapeutics","kind":"company","name":"Tempest Therapeutics","route":"/companies/tempest-therapeutics/"}]}}